Last reviewed · How we verify
Influenza prevention for adults and children 6 years and older — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Licensed Influenza Vaccine 2 | Licensed Influenza Vaccine 2 | BioNTech | Vaccine | Not specified |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- BioNTech · 1 drug in Influenza prevention for adults and children 6 years and older
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Influenza prevention for adults and children 6 years and older:
- Influenza prevention for adults and children 6 years and older treatment updates — RSS
- Influenza prevention for adults and children 6 years and older treatment updates — Atom
- Influenza prevention for adults and children 6 years and older treatment updates — JSON
Cite this brief
Drug Landscape (2026). Influenza prevention for adults and children 6 years and older — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/influenza-prevention-for-adults-and-children-6-years-and-older. Accessed 2026-06-10.
Related
- Influenza prevention for adults and children 6 years and older full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing